A Phase I/IIa Open-label Multi-centre Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of AZD0022 Monotherapy and in Combination with Anti-cancer Agents in Participants with Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01)
This study is a trial to test the tolerability, side effects, and early effectiveness of the drug AZD0022 in patients with advanced tumors that have a KRAS G12D mutation. The trial has three parts. In Part A, doctors will find the highest dose of the drug that causes few side effects. In Part B, they will figure out the best dose to use from part A. In Part C, they will see how well the drug works against cancer. The main goals are to see how many side effects happen, how well the drug works, and how the drug acts in the body.
nys-mothers-bill-of-rights-haitain-creole.pdf
... , kèlkeswa ras ou, kwayans ou, peyi kote ou soti, preferans seksyèl ou, idantite seksyèl ou oswa ekspresyon ...
A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 2003 CLASS III OR IV LUPUS NEPHRITIS
This is a parallel-group, double-blind, randomized, placebo-controlled study comparingthe efficacy and safety of obinutuzumab versus placebo among patients with ISN/RPS2003 Class III or IV LN treated with standard-of-care therapy with MMF andcorticosteroids. The study will enroll approximately 252 patients.Patients must be 18?75 years of age and have ISN/RPS Class III or IV proliferative LNas evidenced by renal biopsy performed in the 6 months prior to screening or duringscreening. Patients may have concomitant Class V disease (i.e., Class III/V orClass IV/V). Patients must exhibit significant proteinuria as evidenced by a UPCR ? 1based on a 24-hour urine collection during screening.Key exclusion criteria include evidence of severe renal impairment, defined by an eGFR? 30 mL/min per 1.73 m2 of body surface area or ESRD requiring dialysis ortransplantation; evidence of active infection; and other safety-related exclusions.The study consists of the following study periods: screening, blinded treatment,open-label treatment (OLT), and study follow-up.
DAY101-002; LOGGIC/FIREFLY-2: A Phase 3 Randomized International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy.
The study is also being done to learn more about how the study drug is absorbed (taken up in the body), metabolized (broken down by the body), distributed (circulated in the body), and eliminated (passed out of the body). The patients will be monitored and taken care of while on these medication during the entire study period.
Esprit BTK Post-Approval Study (PAS)
The purpose of this study is to assess the continued safety and efficacy of the Esprit BTK system, which was recently approved by the Food and Drug Administration (FDA), for treatment of narrowed arteries below the knee in patients with Chronic Limb-Threatening Ischemia (CLTI).
Every patient has one electronic record, streamlining care system-wide | NYU Langone Health
At NYU Langone, our patients use one electronic health record to streamline and integrate care across the health system.
X-Ray Imaging | NYU Langone Health
NYU Langone offers bone, chest, abdominal, and dental X-rays.
policy-133-medical-gas-outlets.pdf
... Safety Policy Manual Policy No. 133 Policy: Medical Gas Outlets and Piping Page 1 of 4 Revised ... -Index Safety System (DISS) Medigas Policy No. 133 Policy: Medical Gas Outlets and Piping Page 2 of 4 ...
<strong>Adolescents:</strong> A Prospective Single Arm Open Label Trial to Confirm Safety and Effectiveness of Prism as an Adjunct to Standard of Care in Adolescents with Post-Traumatic Stress Disorder (PTSD)
The purpose of this research study is to is to establish if the FDA-approved Prism device, currently used for treating adult PTSD patients can also be safely used to help adolescents. For more information, please email TeenPTSDTxStudy@nyulangone.org.
A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors
This is a study testing MOMA-313, a drug that blocks a protein called DNA polymerase theta (Pol?) for prostate cancer with a genetic feature called homologous repair deficiency, most commonly with mutation in the gene BRCA2. The drug is being tested by itself or combined with another drug called olaparib, which blocks a different protein (PARP). There are two groups of patients: one group will get MOMA-313 alone, and the other group will get both MOMA-313 and olaparib. In the first group, doctors will test different doses to find the best amount that is effective and with the least amount of side effects to give patients. If patients do well but don't have a strong response to MOMA-313 alone, they may be switched to get both drugs together. The study will also look at how food ate by a patient affects MOMA-313 and how it interacts with olaparib.